These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 1385561)
1. Phytanic acid alpha-oxidation: accumulation of 2-hydroxyphytanic acid and absence of 2-oxophytanic acid in plasma from patients with peroxisomal disorders. ten Brink HJ; Schor DS; Kok RM; Poll-The BT; Wanders RJ; Jakobs C J Lipid Res; 1992 Oct; 33(10):1449-57. PubMed ID: 1385561 [TBL] [Abstract][Full Text] [Related]
2. Phytanic acid oxidation: normal activation and transport yet defective alpha-hydroxylation of phytanic acid in peroxisomes from Refsum disease and rhizomelic chondrodysplasia punctata. Pahan K; Khan M; Singh I J Lipid Res; 1996 May; 37(5):1137-43. PubMed ID: 8725164 [TBL] [Abstract][Full Text] [Related]
3. Phytanic acid alpha-oxidation in peroxisomal disorders: studies in cultured human fibroblasts. Verhoeven NM; Schor DS; Roe CR; Wanders RJ; Jakobs C Biochim Biophys Acta; 1997 Oct; 1361(3):281-6. PubMed ID: 9375802 [TBL] [Abstract][Full Text] [Related]
4. In vivo study of phytanic acid alpha-oxidation in classic Refsum's disease and chondrodysplasia punctata. ten Brink HJ; Schor DS; Kok RM; Stellaard F; Kneer J; Poll-The BT; Saudubray JM; Jakobs C Pediatr Res; 1992 Nov; 32(5):566-70. PubMed ID: 1282700 [TBL] [Abstract][Full Text] [Related]
5. Studies on the oxidation of phytanic acid and pristanic acid in human fibroblasts by acylcarnitine analysis. Verhoeven NM; Jakobs C; ten Brink HJ; Wanders RJ; Roe CR J Inherit Metab Dis; 1998 Oct; 21(7):753-60. PubMed ID: 9819705 [TBL] [Abstract][Full Text] [Related]
6. Accumulation of pristanic acid (2, 6, 10, 14 tetramethylpentadecanoic acid) in the plasma of patients with generalised peroxisomal dysfunction. Poulos A; Sharp P; Fellenberg AJ; Johnson DW Eur J Pediatr; 1988 Feb; 147(2):143-7. PubMed ID: 2452737 [TBL] [Abstract][Full Text] [Related]
7. Pristanic acid and phytanic acid in plasma from patients with peroxisomal disorders: stable isotope dilution analysis with electron capture negative ion mass fragmentography. ten Brink HJ; Stellaard F; van den Heuvel CM; Kok RM; Schor DS; Wanders RJ; Jakobs C J Lipid Res; 1992 Jan; 33(1):41-7. PubMed ID: 1372637 [TBL] [Abstract][Full Text] [Related]
8. Stereochemistry of the peroxisomal branched-chain fatty acid alpha- and beta-oxidation systems in patients suffering from different peroxisomal disorders. Ferdinandusse S; Rusch H; van Lint AE; Dacremont G; Wanders RJ; Vreken P J Lipid Res; 2002 Mar; 43(3):438-44. PubMed ID: 11893780 [TBL] [Abstract][Full Text] [Related]
9. Evidence against alpha-hydroxyphytanic acid as an intermediate in the metabolism of phytanic acid. Skjeldal OH; Stokke O Scand J Clin Lab Invest; 1988 Feb; 48(1):97-102. PubMed ID: 2464193 [TBL] [Abstract][Full Text] [Related]
10. Clinical and biochemical heterogeneity in conditions with phytanic acid accumulation. Skjeldal OH; Stokke O; Refsum S; Norseth J; Petit H J Neurol Sci; 1987 Jan; 77(1):87-96. PubMed ID: 2433405 [TBL] [Abstract][Full Text] [Related]
11. Phytanic acid alpha-oxidation and complementation analysis of classical Refsum and peroxisomal disorders. Poll-The BT; Skjeldal OH; Stokke O; Poulos A; Demaugre F; Saudubray JM Hum Genet; 1989 Jan; 81(2):175-81. PubMed ID: 2463966 [TBL] [Abstract][Full Text] [Related]
12. The metabolism of phytanic acid and pristanic acid in man: a review. Verhoeven NM; Wanders RJ; Poll-The BT; Saudubray JM; Jakobs C J Inherit Metab Dis; 1998 Oct; 21(7):697-728. PubMed ID: 9819701 [TBL] [Abstract][Full Text] [Related]
13. Disorders related to the metabolism of phytanic acid. Stokke O; Skjeldal OH; Høie K Scand J Clin Lab Invest Suppl; 1986; 184():3-10. PubMed ID: 2438746 [TBL] [Abstract][Full Text] [Related]
14. [Peroxisomal neurologic diseases and Refsum disease: very long chain fatty acids and phytanic acid as diagnostic markers]. Molzer B; Stöckler S; Bernheimer H Wien Klin Wochenschr; 1992; 104(21):665-70. PubMed ID: 1282286 [TBL] [Abstract][Full Text] [Related]
15. Identification and diagnostic value of phytanoyl- and pristanoyl-carnitine in plasma from patients with peroxisomal disorders. Herzog K; van Lenthe H; Wanders RJA; Vaz FM; Waterham HR; Ferdinandusse S Mol Genet Metab; 2017 Jul; 121(3):279-282. PubMed ID: 28566232 [TBL] [Abstract][Full Text] [Related]
16. Localization of the oxidative defect in phytanic acid degradation in patients with Refsum's disease. Mize CE; Herndon JH; Blass JP; Milne GW; Follansbee C; Laudat P; Steinberg D J Clin Invest; 1969 Jun; 48(6):1033-40. PubMed ID: 4181594 [TBL] [Abstract][Full Text] [Related]
17. Peroxisomes, Refsum's disease and the alpha- and omega-oxidation of phytanic acid. Wanders RJ; Komen JC Biochem Soc Trans; 2007 Nov; 35(Pt 5):865-9. PubMed ID: 17956234 [TBL] [Abstract][Full Text] [Related]
18. Phytanic acid alpha-oxidation in rat liver peroxisomes. Production of alpha-hydroxyphytanoyl-CoA and formate is enhanced by dioxygenase cofactors. Mihalik SJ; Rainville AM; Watkins PA Eur J Biochem; 1995 Sep; 232(2):545-51. PubMed ID: 7556205 [TBL] [Abstract][Full Text] [Related]
20. The enzymatic and mass spectrometric identification of 2-oxophytanic acid, a product of the peroxisomal oxidation of l-2-hydroxyphytanic acid. Vamecq J; Draye JP Biomed Environ Mass Spectrom; 1988 Mar; 15(6):345-51. PubMed ID: 3288289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]